Documents reveal McKinsey's role increasing opioid sales until 2019

McKinsey & Company found opportunities to boost opioid manufacturers' sales amid the addiction crisis from 2004 to 2019, new documents published by the University of California at San Francisco and Johns Hopkins University show.

Why it matters: When one opioid fell out of favor with federal regulators, drugmakers created and marketed another, further stoking the crisis.

The more than 114,000 pages of documents show how McKinsey had a much broader role advising the companies than was previously documented, providing growth and turnaround plans to combat the loss of revenue from opioid lawsuits, advice on...